Table 2 Details of the development of the risk scores used for the external validation
Author (year) | Study size (cases of CRC) | Model type | Country | Cancer outcome | Model evaluated in M or F |
|---|---|---|---|---|---|
Driver (2007) [25] | 21,581 (485) | Logistic regression | USA | CRC, C, R | M |
Ma Point (2010) [12] | 18,256 (543) | Point score | Japan | CRC, C, R | M |
Ma Cox (2010) [12] | 18,256 (543) | Logistic regression | Japan | CRC, C, R | M |
Guo (2020) [28] | 92,923 (353) | Point score | China | CRC | M |
Chen (2014) [29] | 905 (38 CRC; 100 AP) | Point score | China | CRC | Both |
Betes (2003) [31] | 2210 (270) | Point score | Spain | CRC | Both |
Aleksandrova (2021) [30] | 255,482 (3645) | Logistic regression | Europe | CRC | Both |
Imperiale (2021) [26] | 3025 (284) | Logistic regression | USA | CRC | Both |
Hong (2017) [27] | 21,762 (1117) | Logistic regression | Korea | CRC | Both |